Oncologix Tech, Inc. (OTCPK:OCLG) acquired Dotolo Research Corporation from Clearview Medical, LLC on March 22, 2013. Under the terms of the agreement, Oncologix Tech will acquire 100 shares of Clearview with an aggregate amount of 58,564 shares of a newly created Series D Preferred Stock. Each share of New Preferred shall be convertible into 1,000 shares of common stock commencing one year after issuance. Under the terms of the agreement, Barry Griffith, the current Chairman and Chief Executive Officer of the Oncologix, resigned from Oncologix and the Board of Directors, and Oncologix's Chief Financial Officer and remaining member of the Board of Directors agreed to remain on the Board for a minimum period of 180 days. Roy W. Erwin will assume the responsibilities of Oncologix as Chairman of the Board and Chief Executive Officer. Michael A. Kramarz will remain as the Chief Financial Officer.

The transaction is subject to due diligence review, receipt of necessary approvals by the state or local authorities, as needed.


Oncologix Tech, Inc. (OTCPK:OCLG) completed the acquisition of Dotolo Research Corporation from Clearview Medical, LLC on March 22, 2013.